Nadofaragene firadenovec-vncg >Immunotherapy Treatments>Nadofaragene firadenovec-vncgImmunotherapy Treatments Immunotherapy TreatmentsDrugs by Tumor TypeImmunotherapy Types for Drug TherapyDrugs A-DAvelumabCemiplimabDostarlimab-gxlyDurvalumabDrugs E-IEpcoritamab-byspIdecabtagene VicleucelIpilimumabIpilimumab/nivolumabDrugs J-NNadofaragene firadenovec-vncgNivolumabNivolumab/hyaluronidaseDrugs O-SPembrolizumabPembrolizumab/ berahyaluronidaseRelatlimab/nivolumabDrugs T-WTalimogene laherparepvec; T-VECTalquetamab-tgvsTarlatamab-dlleTebentafusp-tebnTisotumab vedotin-tftvToripalimab-tpziTremelimumab-actlDrugs X-ZZenocutuzumab-zbco[wpb_childpages] Print 🖨 PDF 📄 Nadofaragene firadenovec-vncg is a non-replicating, vector-based gene therapy designed to deliver the gene encoding the cytokine, interferon-alfa 2b (IFNα2b), into the bladder. Immune cells are recruited into the area of cytokine release. Provider Resource